Old Web
English
Sign In
Acemap
>
authorDetail
>
Amy E. Bock
Amy E. Bock
Pfizer
Adalimumab
Medicine
Rheumatology
Rheumatoid arthritis
Internal medicine
4
Papers
27
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Randomized, Open-Label, Single-Dose, Parallel-Group Pharmacokinetic Study of PF-06410293 (adalimumab-afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects.
2021
Clinical pharmacology in drug development
Donna S. Cox
Daniel F. Alvarez
Amy E. Bock
Carol Cronenberger
Show All
Source
Cite
Save
Citations (0)
Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52, including a treatment switch from reference ADL to PF-06410293.
2021
RMD Open
Roy Fleischmann
Daniel F. Alvarez
Amy E. Bock
Carol Cronenberger
Ivana Vranic
Wuyan Zhang
Rieke Alten
Show All
Source
Cite
Save
Citations (2)
Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial.
2021
Arthritis Research & Therapy
Roy Fleischmann
Daniel F. Alvarez
Amy E. Bock
Carol Cronenberger
Ivana Vranic
Wuyan Zhang
Rieke Alten
Show All
Source
Cite
Save
Citations (0)
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
2018
Arthritis Research & Therapy
R. Fleischmann
Rieke Alten
Margarita Pileckyte
Kasia Lobello
Steven Y. Hua
Carol Cronenberger
Daniel Alvarez
Amy E. Bock
K. Lea Sewell
Show All
Source
Cite
Save
Citations (25)
1